Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Scientific Industries reported a net loss of $2.35 million for the nine months ended September 30, 2026, compared to a net income of $0.69 million in the prior year period. While revenues increased to $4.05 million from $3.43 million, the prior year's profitability was primarily driven by a larger gain on the disposition of discontinued operations.
Mobiquity Technologies reported a significant revenue increase to $334,896 for the nine months ended September 30, 2026, compared to $160,795 in the prior year. However, net loss widened to $8.6 million due to higher general and administrative expenses, resulting in a total stockholders' deficit of $221,189.
Positron Corp filed its Form 10-Q for the quarterly period ended September 30, 2026, detailing its financial performance and operational progress in the molecular imaging industry. The report highlights the company's focus on its PET imaging systems and the development of its radiopharmaceutical business segments.
Calidi Biotherapeutics reported a net loss of $11.9 million for the nine months ended September 30, 2026, compared to a $16.0 million loss in the prior year period. The company maintained a cash balance of $3.9 million as of September 30, 2026, and completed a 1-for-16 reverse stock split in July 2026 to adjust its capital structure.
EQT Private Equity Company LLC reported total investments at fair value of $997.7 million as of September 30, 2026, representing a significant increase from $602.9 million at the end of 2025. The company maintains a diverse share structure across multiple classes and reported $165.6 million in cash and cash equivalents to support its ongoing private equity acquisition strategy.
Stardust Power Inc. reported total assets of $13.4 million and total liabilities of $15.4 million as of September 30, 2026, resulting in a stockholders' deficit. The company faces substantial doubt regarding its ability to continue as a going concern following its delisting from Nasdaq and transition to the Pink Limited Market.
Guru App Factory Corp reported a decline in revenue from $94,500 in 2025 to $52,000 in 2026, primarily due to the non-recurrence of a large software development order. The company's net loss widened to $59,440, and its independent auditor issued a going concern warning due to a working capital deficit and accumulated deficit of $126,863.
Highview Merger Corp. reported a net income of $5.37 million for the nine months ended September 30, 2026, primarily driven by $6.24 million in interest earned on marketable securities held in the Trust Account. As a shell company, its activities are focused on identifying a target for a business combination, with $239.85 million currently held in trust for potential redemptions.
EQT Infrastructure Company LLC reported total investments at fair value of $886.6 million as of September 30, 2026, a significant increase from zero at the end of 2025 following its initial offering in February 2026. The company maintains a complex share structure with over 44 million shares outstanding across various classes, primarily focused on acquiring and managing portfolio companies through joint ventures.
Twelve Seas Investment Company III is a shell company that completed its IPO on December 15, 2025, raising $172.5 million held in trust. As of September 30, 2026, the company has 17,745,000 Class A and 5,692,500 Class B ordinary shares outstanding and is seeking a business combination within a 24-month window ending December 15, 2027.
Beyond Air reported record quarterly revenue of $2.3 million for the period ended September 30, 2026, representing 28% year-over-year growth. The company reaffirmed its revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 while awaiting FDA approval for its second-generation LungFit PH system.
Term
Q2 2027
“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval.”
Robert Goodman, Chief Executive Officer of Beyond Air
“We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system.”
Robert Goodman, Chief Executive Officer of Beyond Air
Spruce Power Holding Corp reported 19,294,133 shares of common stock outstanding as of November 9, 2026. The company's cash and cash equivalents decreased from $54.8 million at the end of 2025 to $40.1 million as of September 30, 2026, while management highlighted risks related to debt refinancing and solar industry demand.
Evofem Biosciences reported Q3 2026 financial results, achieving $0.7 million in operating income despite a slight decline in net sales to $4.6 million. The company highlighted the shipment of its 500,000th box of PHEXX and the addition of a fifth study site for an NIH-funded Phase 4 trial of SOLOSEC.
Term
Q3 2026
“While third quarter net sales reflect the cumulative impact of operating without dedicated growth capital for brand promotion and physician outreach since late 2022, we are proud of the discipline, efficiency and tenacity demonstrated across the organization. Through rigorous expense management, we generated $0.7 million of operating income during the quarter while continuing to support patients and healthcare providers who rely on our innovative sexual health products.”
BioScience Health Innovations, Inc. reported a net loss of $564,885 for the nine months ended September 30, 2026, a significant decline from the $875,720 net income in the prior year period. Despite the loss, the company successfully raised over $2 million through common stock sales, ending the period with a strengthened cash position of $1,691,858.
KKR Private Equity Conglomerate LLC reported a net increase in net assets resulting from operations of $975.5 million for the nine months ended September 30, 2026, compared to $762.1 million in the prior year period. Total assets grew to $13.6 billion, driven by a significant increase in investments at fair value and cash holdings.
Evofem Biosciences reported a significant decline in total assets from $20.3 million at year-end 2025 to $7.3 million as of September 30, 2026, driven largely by a decrease in trade accounts receivable and intangible assets. The company faces substantial liquidity challenges with $84.8 million in current liabilities and has received notices of default from Future Pak, LLC regarding its debt obligations.
Senior Credit Investments, LLC reported a net increase in member’s capital resulting from operations of $18.4 million for the nine months ended September 30, 2026, up from $12.0 million in the prior year period. Total investment income grew significantly to $40.4 million, driven by interest income from its non-controlled/non-affiliated investment portfolio, while net asset value per unit decreased slightly to $1,767.94 from $1,787.98 at year-end 2025.
Jefferies Credit Partners BDC Inc. reported a net increase in net assets resulting from operations of $52.0 million for the nine months ended September 30, 2026, compared to $30.5 million for the same period in 2025. Total net assets grew to $964.9 million from $677.0 million at year-end 2025, driven by significant capital share issuances and investment income growth.
The 21Shares Solana Staking ETF reported net assets of $9,786,070 as of September 30, 2026, a significant increase from $5,735,019 at the end of 2025. The Trust generated $102,143 in staking rewards for the nine months ended September 30, 2026, and transitioned its pricing benchmark to the FTSE Solana Index in August 2026.
Blue Line Holdings, Inc. remains a pre-revenue industrial company with a net loss of $12,459 for the quarter ended September 30, 2026. The company reported a working capital deficit of $90,521 and expressed substantial doubt regarding its ability to continue as a going concern without additional financing.
For the quarter ended September 30, 2026, INVE Technologies reported a net income of $0.6 million, a significant improvement from a $3.5 million loss in the prior year, primarily driven by a $6.1 million gain on an asset sale. However, total revenue decreased to $3.1 million from $5.0 million year-over-year, and the company recorded a nine-month net loss of $7.5 million.
Femasys Inc. reported a decrease in sales for the nine months ended September 30, 2026, totaling $1,161,313 compared to $1,479,926 in the prior year period. The company significantly strengthened its balance sheet, ending the quarter with $23.9 million in cash and cash equivalents following financing activities, while maintaining an accumulated deficit of $154 million.
Edgemode, Inc. reported a net loss of $10.5 million for the nine months ended September 30, 2026, compared to a loss of $14.4 million in the prior year period. The company's balance sheet shows a significant stockholders' deficit of $7.6 million and a substantial reduction in derivative liabilities from $15.4 million to $1.5 million during the year.
American Strategic Investment Co. reported a net loss of $22.8 million for the nine months ended September 30, 2026, compared to a $14.5 million loss in the prior year. The company's total equity decreased to $47.3 million from $64.8 million at year-end 2025, primarily driven by the net loss and offset by common stock issuances to its Advisor.
This document is a formal consent from Altus Group U.S., Inc. allowing Hines Global Income Trust, Inc. to reference their role as an independent valuer in the company's Q3 2026 Quarterly Report. It specifically pertains to the valuation process described in the Net Asset Value section of the filing.
Origin Investment Corp I reported a net income of $1,165,890 for the nine months ended September 30, 2026, primarily driven by $1,937,643 in interest income from its Trust Account. As a blank check company, it has not yet commenced operations or generated revenue, and its total assets of $73.36 million are largely comprised of investments held in trust for a future business combination.
Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.
Term
Q3 2026
“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”
Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
CKX Lands, Inc. reported net income of $621,499 for the nine months ended September 30, 2026, an increase from $442,919 in the prior year period, driven largely by higher surface revenue and interest income. Total assets remained stable at approximately $22.4 million, while the company maintained a strong liquidity position with $15.9 million in cash and cash equivalents.
Seritage Growth Properties reported Q3 2026 financial results, achieving net income of $2.7 million compared to a net loss for the nine-month period. The company generated $3.0 million from asset sales and received an $8.9 million distribution from an unconsolidated entity, while continuing to evaluate strategic options for its remaining portfolio.
Term
Q3 2026
“Although we have no new transactions under contract, we continue to work on both individual asset sales and potential strategic options for the portfolio and the Company”
Grown Rogue International Inc. reported total revenue of $31.45 million for the nine months ended September 30, 2026, compared to $23.67 million in the prior year period. The company experienced a net loss of $12.58 million for the nine-month period, primarily driven by a $5.03 million loss on the acquisition of Rogue EBC and significant increases in general and administrative expenses.